Joshua T. Brumm Net Worth

The estimated Net Worth of Joshua T Brumm is at least $34.6 Milión dollars as of 8 March 2024. Mr Brumm owns over 429,730 units of Dyne Therapeutics stock worth over $17,538,735 and over the last 8 years he sold DYN stock worth over $16,266,955. In addition, he makes $789,444 as CEO a Pres & Director at Dyne Therapeutics.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr Brumm DYN stock SEC Form 4 insiders trading

Mr has made over 20 trades of the Dyne Therapeutics stock since 2016, according to the Form 4 filled with the SEC. Most recently he sold 429,730 units of DYN stock worth $11,125,710 on 8 March 2024.

The largest trade he's ever made was selling 429,730 units of Dyne Therapeutics stock on 8 March 2024 worth over $11,125,710. On average, Mr trades about 44,817 units every 83 days since 2016. As of 8 March 2024 he still owns at least 537,998 units of Dyne Therapeutics stock.

You can see the complete history of Mr Brumm stock trades at the bottom of the page.

Mr. Joshua T. Brumm biography

Joshua T. Brumm is the CEO, Pres & Director at Dyne Therapeutics.

What is the salary of Mr Brumm?

As the CEO a Pres & Director of Dyne Therapeutics, the total compensation of Mr Brumm at Dyne Therapeutics is $789,444. There are 2 executives at Dyne Therapeutics getting paid more, with Dewei Qiao having the highest compensation of $2,036,560.

How old is Mr Brumm?

Mr Brumm is 43, he's been the CEO a Pres & Director of Dyne Therapeutics since . There are 19 older and 5 younger executives at Dyne Therapeutics. The oldest executive at Dyne Therapeutics, Inc. is Yuezhou Ou, 68, who is the Independent Non-Executive Director.

What's Mr Brumm's mailing address?

Joshua's mailing address filed with the SEC is 1560 TRAPELO ROAD, , WALTHAM, MA, 02451.

Insiders trading at Dyne Therapeutics

Over the last 4 years, insiders at Dyne Therapeutics have traded over $197,573,300 worth of Dyne Therapeutics stock and bought 5,790,447 units worth $92,382,301 . The most active insiders traders include Capital Management, L.P.Kol..., Jason P Rhodes a Dirk Kersten. On average, Dyne Therapeutics executives and independent directors trade stock every 12 days with the average trade being worth of $3,566,016. The most recent stock trade was executed by Oxana Beskrovnaya on 11 September 2024, trading 2,161 units of DYN stock currently worth $68,914.

What does Dyne Therapeutics do?

Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and cardiac and metabolic muscle diseases using its FORCE platform that delivers disease-modifying therapeutics. The company was incorporated in 2017 and is headquartered in Waltham, Massachusetts..

Complete history of Mr Brumm stock trades at Kaleido Biosciences Inc a Dyne Therapeutics

Dyne Therapeutics executives and stock owners

Dyne Therapeutics executives and other stock owners filed with the SEC include:

• Dewei Qiao,
  General Manager, Executive Director
• Shengyong Hu,
  Chief Financial Officer, Executive Director
• Joshua T. Brumm,
  CEO, Pres & Director
• Dr. Romesh Subramanian Ph.D.,
  Co-Founder & Advisor
• Susanna Gatti High M.B.A.,
  Chief Operating Officer
• Lanjun Xie,
  Non-Executive Independent Director
• Yuezhou Ou,
  Independent Non-Executive Director
• Jie Fu,
  Non-Executive Independent Director
• Shuguang Liu,
  Non-Executive Director
• Sunning Cheng,
  Non-Executive Director
• Jinjun Cao,
  Non-Executive Director
• Wing Yan Yuen,
  Company Secretary
• Shuguang Zhu,
  Deputy General Manager and Secretary of the Board
• Yong Zhang,
  Deputy General Manager
• Jianzhong Huang,
  Deputy General Manager
• Yan Cheng,
  Deputy General Manager
• Jun Zhi,
  Non-Executive Chairman of the Board
• Kate Mitchell,
  VP & Head of HR
• Richard William Scalzo M.B.A.,
  Sr. VP, Head of Fin. & Admin. and Treasurer
• Dr. Thomas-Christian Mix M.D., M.S.,
  Sr. VP of Clinical Devel.
• Richard William Scalzo,
  VP of Accounting & Admin. and Treasurer
• Daniel Wilson,
  VP & Head of Intellectual Property
• Debra Feldman,
  VP & Head of Regulatory Affairs
• Dr. Thomas-Christian Mix M.D.,
  Sr. VP of Clinical Devel.
• Dr. Oxana Beskrovnaya Ph.D.,
  Chief Scientific Officer
• Amy Reilly,
  VP of Corp. Communications & Investor Relations
• Richard Scalzo,
  VP of Accounting & Admin. and Treasurer
• Gene Kim,
  VP of Fin.
• Johanna Friedl Naderer,
  Chief Commercial Officer
• Lawrence Otto Klein,
  Director
• Capital Fund Iv Cooperatief...,
  10% owner
• Global Management Lp Logos,
  10% owner
• Dirk Kersten,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Romesh Subramanian,
  Chief Scientific Officer
• Susanna Gatti High,
  Chief Operating Officer
• Douglas Kerr,
  Chief Medical Officer
• Edward Hurwitz,
  
• Carlo Incerti,
  
• David Charles Lubner,
  
• Bioventures 2018, L.P.Mpm B...,
  
• Venture Fund Xi, L.P.Atlas ...,
  
• Capital Management, L.P.Kol...,
  
• Biomedical Innovation Maste...,
  10% owner
• Jason P Rhodes,
  
• Ventures, Llc Cure Duchenne,
  10% owner
• Manager Ii, Llc Vida Ventur...,
  
• Catherine Stehman Breen,
  
• Venture Opportunity Fund Ii...,
  
• Venture Fund Xi, L.P. Atlas,
  10% owner
• Venture Fund Xi, L.P.Atlas ...,
  
• John Cox,
  CEO & President
• Wildon Farwell,
  Chief Medical Officer
• Jonathan Mc Neill,
  Chief Business Officer
• Richard William Scalzo,
  SVP, Head of Finance & Admin.
• Joshua T Brumm,
  CEO & President
• Oxana Beskrovnaya,
  Chief Scientific Officer
• Venture Opportunity Fund I,...,